Erasca faces claims. JPMorgan targets Erasca stock at USD 33.00

Published on 10/02/2026 at 00:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A notice revisited ERAS-0015 claims on October 1, 2026. For Erasca stock, second-quarter 2026 GAAP loss reached USD 44.08 million.

ERAS, US29479A1088, Illustration mit AI erstellt.

Erasca, Inc. (ISIN US29479A1088) faces securities claims tied to ERAS-0015 disclosures in a notice dated October 1, 2026, while JPMorgan maintained a USD 33.00 price target on August 27, 2026. GlobeNewswire reported that Grabar Law Office was investigating whether company officers and directors breached fiduciary duties. Investing.com listed JPMorgan's maintained target on August 27, 2026.

ERAS-0015 claims raise disclosure risks

The notice links the investigation to public statements about ERAS-0015, Erasca's pan-RAS molecular glue candidate for RAS-mutant solid tumors. It says the underlying complaint alleges that comparisons with Revolution Medicines' RMC-6236 did not adequately explain intellectual-property, patent and trade-secret risks.

GlobeNewswire also cited April 27, 2026 disclosures in which Erasca reported preliminary Phase 1 data and acknowledged that cross-study comparisons were inherently limited. The legal notice presents these points as allegations, not as an adjudicated finding.

Second-quarter loss stays substantial

Erasca reported a second-quarter 2026 GAAP net loss of USD 44.08 million and diluted earnings per share of minus USD 0.14. MarketBeat said the quarterly loss missed consensus of minus USD 0.11 by USD 0.03, making the earnings comparison a direct test of the company's clinical spending profile.

The company remains a clinical-stage biotechnology developer focused on therapies for cancers driven by the RAS/MAPK pathway. Its pipeline includes ERAS-0015 and other targeted candidates, so legal scrutiny and clinical evidence remain closely connected in the investment case.

Nasdaq range frames the valuation

ERAS is listed on Nasdaq. Its 52-week range was USD 2.10 to USD 24.28 as of October 1, 2026, while market capitalization stood at USD 5.1 billion on the same date. The range places the stock well below its yearly high, while the disclosure dispute adds a separate legal risk to the clinical development story.